Division of Cancer & Genetics, School of Medicine, Cardiff University, Cardiff, UK.
National Imaging Academy of Wales (NIAW), Pencoed, UK.
Br J Radiol. 2022 Sep 1;95(1137):20220152. doi: 10.1259/bjr.20220152. Epub 2022 Jul 21.
To estimate the risk of malignancy in gallbladder polyps of incremental sizes detected during transabdominal ultrasound (TAUS).
We searched databases including MEDLINE, Embase, and Cochrane Library for eligible studies recording the polyp size from which gallbladder malignancy developed, confirmed following cholecystectomy, or by subsequent follow-up. Primary outcome was the risk of gallbladder cancer in patients with polyps. Secondary outcome was the effect of polyp size as a prognostic factor for cancer. Risk of bias was assessed using the Quality in Prognostic Factor Studies (QUIPS) tool. Bayesian meta-analysis estimated the median cancer risk according to polyp size. This study is registered with PROSPERO (CRD42020223629).
82 studies published since 1990 reported primary data for 67,837 patients. 67,774 gallbladder polyps and 889 cancers were reported. The cumulative median cancer risk of a polyp measuring 10 mm or less was 0.60% (99% credible range 0.30-1.16%). Substantial heterogeneity existed between studies (I = 99.95%, 95% credible interval 99.86-99.98%). Risk of bias was generally high and overall confidence in evidence was low. 13 studies (15.6%) were graded with very low certainty, 56 studies (68.3%) with low certainty, and 13 studies (15.6%) with moderate certainty. In studies considered moderate quality, TAUS monitoring detected 4.6 cancers per 10,000 patients with polyps less than 10 mm.
Malignant risk in gallbladder polyps is low, particularly in polyps less than 10 mm, however the data are heterogenous and generally low quality. International guidelines, which have not previously modelled size data, should be informed by these findings.
This large systematic review and meta-analysis has shown that the mean cumulative risk of small gallbladder polyps is low, but heterogeneity and missing data in larger polyp sizes (>10 mm) means the risk is uncertain and may be higher than estimated.Studies considered to have better methodological quality suggest that previous estimates of risk are likely to be inflated.
评估经腹超声(TAUS)检测到的渐进性大小的胆囊息肉恶变的风险。
我们检索了包括 MEDLINE、Embase 和 Cochrane 图书馆在内的数据库,以获取记录胆囊息肉大小的研究,这些息肉是在胆囊切除术后或通过后续随访中发现的,并已确认存在恶性肿瘤。主要结局是患者患有胆囊癌的风险。次要结局是息肉大小作为预后因素的效果。使用预后因素研究质量(QUIPS)工具评估偏倚风险。贝叶斯荟萃分析根据息肉大小估计中位癌症风险。本研究已在 PROSPERO(CRD42020223629)注册。
自 1990 年以来,82 项研究发表了 67837 例患者的原始数据。报告了 67774 个胆囊息肉和 889 例癌症。直径为 10mm 或以下的息肉累积癌症风险为 0.60%(99%可信区间 0.30-1.16%)。研究之间存在很大的异质性(I = 99.95%,99.86-99.98%可信区间)。偏倚风险普遍较高,证据总体可信度较低。13 项研究(15.6%)被评为极低确定性,56 项研究(68.3%)为低确定性,13 项研究(15.6%)为中确定性。在被认为具有中等质量的研究中,TAUS 监测在直径小于 10mm 的息肉患者中每 10000 例发现 4.6 例癌症。
胆囊息肉的恶性风险较低,特别是直径小于 10mm 的息肉,但数据存在异质性且总体质量较低。以前没有对大小数据进行建模的国际指南应参考这些发现。
这项大型系统评价和荟萃分析表明,小胆囊息肉的平均累积风险较低,但较大息肉(>10mm)的异质性和数据缺失意味着风险不确定,可能高于估计值。被认为具有较好方法学质量的研究表明,以前对风险的估计可能被夸大了。